Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma

Abstract

Recently, serum miRNAs have been evolved as possible biomarkers for different diseases including hepatocellular carcinoma and other types of cancers. Investigating certain serum miRNAs as novel non-invasive markers for early detection of HCV-positive cirrhosis and hepatocellular carcinoma (HCC). The expression profiles of 58 miRNA were analyzed in patient's plasma of chronic hepatitis C (CHC), HCV-positive cirrhosis and HCV-positive HCC and compared with control group samples. Totally 94 plasma samples; 64 patient plasma (26 CHC, 30 HCV-positive cirrhosis, 8 HCV-positive HCC) and 28 control group plasma, were included. The expression profiles of 58 miRNAs were detected for all patient and control group plasma samples by qRT-PCR using BioMarkTM 96.96 Dynamic Array (Fluidigm Corporation) system. In CHC group, expression profiles of miR-30a-5p, miR-30c-5p, miR-206 and miR-302c-3p were found significantly deregulated (p < 0.05) when compared versus control group. In HCV-positive cirrhosis group, expression profiles of miR-30c-5p, miR-223-3p, miR-302c-3p, miR-17-5p, miR-130a-3p, miR-93-5p, miR-302c-5p and miR-223-3p were found significantly deregulated (p < 0.05). In HCV-positive HCC group, expression profiles of miR-17-5p, miR-223-3p and miR-24-3p were found significant (p < 0.05). When all groups were compared versus control, miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p were found significantly deregulated for cirrhosis and HCC. These results imply that miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers of HCV-positive HCC in very early, even at cirrhosis stage of liver disease.

Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison

“…Besides chemicals, particularly reactive oxygen species were positively mutagenic for adjacent cancer cells, accelerating their genetic evolution towards the high malignant carcinoma80. In blood, the increased expression of miR-30c-5p could be used as a new classifier for HCV-positive HCC in early-stage81. In addition, hepatic necroinflammatory activity was associated with the high expression of miR-122-5p in plasma.…”

Identifying microRNA panels specifically associated with hepatocellular carcinoma and its different etiologies

“…For example, miR-24 was found significantly up-regulated in HCC tumor tissue, cell lines, [37,38] and serum compared with healthy controls and/or chronic liver disease patients. [39,40] Serum miR-505 level was also increased in HCC cases compared to controls. [41] The expression of miR-130a was significantly higher in HCV-infected hepatocytes and liver biopsy specimens.…”

PABPC1 interacts with AGO2 and is responsible for the microRNA mediated gene silencing in high grade hepatocellular carcinoma

“…Many miRNAs have been shown to be aberrantly expressed in HCC patients' tissues and serum [19][20][21][22]. In addition, at least 23 miRNAs might have diagnostic and prognostic significance in HCC [23].…”